Browsing Category
Pharma Industry News
4141 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Kodiak Sciences (NASDAQ: KOD) bets Phase 3 momentum and 2027 cash runway can turn pipeline promise into a retina franchise
Kodiak Sciences is chasing a retina comeback with Phase 3 Zenkuda data, a longer cash runway, and major catalysts ahead. Read what happens next.
Does CADENCE confirm a scalable pathway for treating complex pulmonary vascular disease beyond pulmonary arterial hypertension?
WINREVAIR’s Phase 2 data signals expansion beyond pulmonary arterial hypertension. Find out what this means for Merck & Co., Inc. and the market.
AVCT near 52-week high as Avacta doses first patient in AVA6103 Phase 1 trial
Avacta (AVCT) has treated the first patient in the FOCUS-01 Phase 1 trial of AVA6103, its Gen Two pre|CISION exatecan PDC. Initial data expected late 2026. Read more.
AviadoBio opens fourth ASPIRE-FTD cohort as AVB-101 regains full development rights and secures fresh backing from leading dementia foundations
AviadoBio opens the fourth ASPIRE-FTD cohort, regains full AVB-101 rights from Astellas, and secures ADDF backing. Read what it means for FTD gene therapy.
A new Vabysmo challenger? Innovent Biologics’ IBI324 just made the retinal drug race more interesting
Innovent Biologics is advancing IBI324 into Phase 3 after new retinal disease data versus Vabysmo. Read what it could mean for ophthalmology now.
Bristol Myers Squibb (NYSE: BMY) strengthens Camzyos growth case with positive adolescent SCOUT-HCM data
Bristol Myers Squibb’s Camzyos cleared a key adolescent Phase 3 hurdle in oHCM. Read what the SCOUT-HCM data could mean for growth and competition.
What clinicians and regulators may question as GLP-1 therapies move into consumer health platforms
Discover how Hims & Hers and Novo Nordisk are reshaping GLP-1 access and what it means for pricing, regulation, and long-term care models.
Is delivery, not biology, the real key to Alzheimer’s breakthroughs? Lunai Bioworks Inc. is testing it
Can Lunai Bioworks Inc. solve Alzheimer’s drug delivery challenges? Discover what its BBB platform means for CNS innovation and investor outlook.
Corcept Therapeutics (NASDAQ: CORT) puts resistant hypertension in the cortisol spotlight with new MOMENTUM trial data
Corcept Therapeutics says 27.3% of resistant hypertension patients may have hypercortisolism. Read what the MOMENTUM data could mean next.
Incyte (NASDAQ: INCY) moves closer to an hidradenitis suppurativa launch as 54-week povorcitinib data hold up
Incyte Corporation’s new 54-week povorcitinib data could reshape hidradenitis suppurativa treatment. Read what it means for INCY now.